Immune profiles in primary squamous cell carcinoma of the head and neck

Vassiliki Saloura, Evgeny Izumchenko, Zhixiang Zuo, R. Bao, Michael Korzinkin, Ivan Ozerov, Alex Zhavoronkov, D. Sidransky, Atul Bedi, Mohammad O. Hoque, Hartmut Koeppen, Michaela K. Keck, Arun Khattri, N. London, Nikita Kotlov, A. Fatima, Theodore Vougiouklakis, Yusuke Nakamura, Mark Lingen, Nishant AgrawalPeter A. Savage, Stephen Kron, Justin Kline, Marcin Kowanetz, Tanguy Y. Seiwert

Research output: Contribution to journalArticle

Abstract

Objectives: In this study we describe the tumor microenvironment, the signaling pathways and genetic alterations associated with the presence or absence of CD8+ T-cell infiltration in primary squamous cell carcinoma of the head and neck (SCCHN) tumors. Materials and Methods: Two SCCHN multi-analyte cohorts were utilized, the Cancer Genome Atlas (TCGA) and the Chicago Head and Neck Genomics (CHGC) cohort. A well-established chemokine signature classified SCCHN tumors into high and low CD8+ T-cell inflamed phenotypes (TCIP-H, TCIP-L respectively). Gene set enrichment and iPANDA analyses were conducted to dissect differences in signaling pathways, somatic mutations and copy number aberrations for TCIP-H versus TCIP-L tumors, stratified by HPV status. Results: TCIP-H SCCHN tumors were enriched in multiple immune checkpoints irrespective of HPV-status. HPV-positive tumors were enriched in markers of T-regulatory cells (Tregs) and HPV-negative tumors in protumorigenic M2 macrophages. TCIP-L SCCHN tumors were enriched for the β-catenin/WNT and Hedgehog signaling pathways, had frequent mutations in NSD1, amplifications in EGFR and YAP1, as well as CDKN2A deletions. TCIP-H SCCHN tumors were associated with the MAPK/ERK, JAK/STAT and mTOR/AKT signaling pathways, and were enriched in CASP8, EP300, EPHA2, HRAS mutations, CD274, PDCD1LG2, JAK2 amplifications. Conclusions: Our findings support that combinatorial immune checkpoint blockade and depletion strategies targeting Tregs in HPV-positive and M2 macrophages in HPV-negative tumors may lead to improved antitumor immune responses in patients with TCIP-H SCCHN. We highlight novel pathways and genetic events that may serve as candidate biomarkers and novel targeted therapies to enhance the efficacy of immunotherapy in SCCHN patients.

Original languageEnglish (US)
Pages (from-to)77-88
Number of pages12
JournalOral Oncology
Volume96
DOIs
StatePublished - Sep 1 2019

    Fingerprint

Keywords

  • Head and neck cancer
  • Immune checkpoints
  • T-cell inflamed phenotype

ASJC Scopus subject areas

  • Oral Surgery
  • Oncology
  • Cancer Research

Cite this

Saloura, V., Izumchenko, E., Zuo, Z., Bao, R., Korzinkin, M., Ozerov, I., Zhavoronkov, A., Sidransky, D., Bedi, A., Hoque, M. O., Koeppen, H., Keck, M. K., Khattri, A., London, N., Kotlov, N., Fatima, A., Vougiouklakis, T., Nakamura, Y., Lingen, M., ... Seiwert, T. Y. (2019). Immune profiles in primary squamous cell carcinoma of the head and neck. Oral Oncology, 96, 77-88. https://doi.org/10.1016/j.oraloncology.2019.06.032